Catalent, Inc. or Exelixis, Inc.: Who Manages SG&A Costs Better?

Catalent, Inc. vs. Exelixis, Inc.: A Decade of SG&A Management

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Catalent, Inc. and Exelixis, Inc. have demonstrated contrasting approaches to SG&A cost management.

Catalent, Inc. has seen a steady increase in SG&A expenses, rising from approximately $334 million in 2014 to a peak of $935 million in 2024. This represents a growth of nearly 180% over the period. In contrast, Exelixis, Inc. started with a modest $51 million in 2014, reaching $543 million by 2023, marking an impressive increase of over 960%.

While Catalent's expenses have consistently been higher, Exelixis has shown a more rapid growth rate. The data for 2024 is incomplete for Exelixis, indicating potential volatility or strategic shifts. Understanding these trends can provide valuable insights into each company's operational strategies and financial health.